10x Genomics Inc (NASDAQ: TXG) has seen a decline in its stock price by -1.83 in relation to its previous close of 9.85. However, the company has experienced a -12.96% decline in its stock price over the last five trading sessions. prnewswire.com reported 2025-03-03 that 10x Genomics’ ATAC-Seq patents found valid and infringed PLEASANTON, Calif., March 3, 2025 /PRNewswire/ — 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences.
Is It Worth Investing in 10x Genomics Inc (NASDAQ: TXG) Right Now?
Moreover, the 36-month beta value for TXG is 2.00. Analysts have varying opinions on the stock, with 5 analysts rating it as a “buy,” 2 as “overweight,” 9 as “hold,” and 0 as “sell.”
The public float for TXG is 101.39M and currently, short sellers hold a 11.16% of that float. On March 04, 2025, TXG’s average trading volume was 2.33M shares.
TXG’s Market Performance
TXG stock saw a decrease of -12.96% in the past week, with a monthly decline of -35.53% and a quarterly a decrease of -37.53%. The volatility ratio for the week is 6.20%, and the volatility levels for the last 30 days are 7.44% for 10x Genomics Inc (TXG). The simple moving average for the last 20 days is -19.35% for TXG stock, with a simple moving average of -45.84% for the last 200 days.
Analysts’ Opinion of TXG
Many brokerage firms have already submitted their reports for TXG stocks, with Leerink Partners repeating the rating for TXG by listing it as a “Market Perform.” The predicted price for TXG in the upcoming period, according to Leerink Partners is $12 based on the research report published on February 13, 2025 of the current year 2025.
Leerink Partners, on the other hand, stated in their research note that they expect to see TXG reach a price target of $35. The rating they have provided for TXG stocks is “Outperform” according to the report published on September 03rd, 2024.
Jefferies gave a rating of “Buy” to TXG, setting the target price at $24 in the report published on July 22nd of the previous year.
TXG Trading at -29.77% from the 50-Day Moving Average
After a stumble in the market that brought TXG to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -78.79% of loss for the given period.
Volatility was left at 7.44%, however, over the last 30 days, the volatility rate increased by 6.20%, as shares sank -32.60% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -33.83% lower at present.
During the last 5 trading sessions, TXG fell by -12.33%, which changed the moving average for the period of 200-days by -63.33% in comparison to the 20-day moving average, which settled at $11.99. In addition, 10x Genomics Inc saw -32.66% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TXG starting from Serge Saxonov, who proposed sale 7,942 shares at the price of $10.57 back on Feb 28 ’25. After this action, Serge Saxonov now owns shares of 10x Genomics Inc, valued at $83,947 using the latest closing price.
Hindson Benjamin J., the insider of 10x Genomics Inc, sale 4,573 shares at $11.07 during a trade that took place back on Feb 24 ’25, which means that Hindson Benjamin J. is holding 335,324 shares at $50,603 based on the most recent closing price.
Stock Fundamentals for TXG
Current profitability levels for the company are sitting at:
- -0.32 for the present operating margin
- 0.69 for the gross margin
The net margin for 10x Genomics Inc stands at -0.3. The total capital return value is set at -0.24. Equity return is now at value -25.17, with -19.39 for asset returns.
Based on 10x Genomics Inc (TXG), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at 0.08. The debt to equity ratio resting at 0.12. The interest coverage ratio of the stock is -48114.75.
Currently, EBITDA for the company is -133.99 million with net debt to EBITDA at 1.95. When we switch over and look at the enterprise to sales, we see a ratio of 1.52. The receivables turnover for the company is 6.95for trailing twelve months and the total asset turnover is 0.66. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.97.
Conclusion
To wrap up, the performance of 10x Genomics Inc (TXG) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
